Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found no evidence that medications used to manage PCOS add to cardiovascular risk or prevent diabetes onset, although metformin may help prevent gestational diabetes in these patients.

This study reports that women with polycystic ovary syndrome, especially those with a hyperandrogenic pattern, are at a higher risk for cardiovascular disease compared to other PCOS patients, likely due to related metabolic comorbidities.

This study suggests that sodium-glucose cotransporter-2 inhibitors, alone or with metformin or GLP1RA, may improve metabolic and hormonal parameters in women with polycystic ovary syndrome.

The studies reviewed found favorable treatment outcomes for hypopigmented scars using PGF2α agonists with no adverse events reported. However, the authors highlight the need for larger randomized controlled trials to better understand their effectiveness and long-term safety.

This review suggests that, among non-hormonal treatments for menstrual irregularities in adolescents with PCOS, metformin is the most effective and cost-efficient option, particularly in overweight adolescent girls.

Hormonal contraceptives and therapies regulate organ functions and treat various conditions.

This review discusses various weight loss treatment options for managing PCOS in women, including lifestyle changes, diet, medications, and surgery, but reports no new clinical results.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

Metabolic issues may trigger lymphocytic cicatricial alopecia, and treatments targeting these issues could help.

This study found that adults with type 2 diabetes or obesity using semaglutide and tirzepatide experienced higher odds of nonscarring alopecia, such as telogen effluvium, compared to those using other GLP-1 receptor agonists, with hair loss potentially linked to physiologic stress from weight loss.

In this study, patient-reported outcomes indicated that greater weight loss with GLP-1RA treatments was associated with increased reports of adverse cosmetic effects such as skin laxity, facial volume loss, and hair shedding, despite improvements in some preexisting inflammatory skin conditions.

This review discusses how glucagon-like peptide-1 receptor agonists, used for type 2 diabetes and obesity, may cause skin aging and hair loss, and explores methylene blue as a potential protective treatment.

This review explores how metabolic and psychological factors contribute to binge eating disorder in women with PCOS and highlights the need for non-punitive, comprehensive management strategies.

This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.

This narrative review found that combined oral contraceptives remain the primary treatment for hirsutism and acne in women with PCOS, but highlighted the need for further research to refine therapeutic options given the variable efficacy and emerging treatments like GLP-1 receptor agonists.

This study identified hypericin and berberine as compounds that can support hair growth by enhancing oxytocin receptor expression and acting as an oxytocin receptor agonist, respectively, potentially serving as practical alternatives to oxytocin for treating hair-loss diseases.

This review explores weight loss interventions during gestation, emphasizing incretin-based therapies' potential to enhance reproductive health and address metabolic changes for better maternal and fetal outcomes.

This review reports that lifestyle modification, including diet and exercise, is essential for managing PCOS, while pharmacological and complementary treatments address specific symptoms like menstrual irregularities and insulin resistance.

This review examines current evidence on personalized management strategies for PCOS, but does not present new clinical results; the authors advocate for treatments tailored to predominant symptoms and individual health profiles.

This study reviews advances in targeted therapies for moderate-severe dermatological conditions like plaque psoriasis and atopic dermatitis, reporting on newly approved treatments and highlighting the need for further innovations in managing rare inflammatory skin diseases through emerging laboratory techniques and trials.

This abstract does not report specific research results but introduces a book focusing on the intersection of endocrinology and aesthetic medicine and its growing importance in contemporary clinical practice.

This review observed that semaglutide may have therapeutic benefits for skin conditions like psoriasis and hidradenitis suppurativa, but reports of adverse skin reactions exist, indicating the need for further research to understand its safety and efficacy in dermatology.

In this case study, a patient developed a rash consistent with acute generalized exanthematous pustulosis after increasing the dose of semaglutide, suggesting that the reaction was likely due to the excipient propylene glycol, highlighting the importance of ingredient analysis and multidisciplinary collaboration for patient safety.

This study examines the pathogenetic role of hormonal imbalances in chronic prostatitis, highlighting that decreased androgens and increased estrogens contribute to prostate inflammation and impaired spermatogenesis, and explores hormonal therapies' potential for restoring reproductive function.

This narrative review identifies telogen effluvium as a growing concern linked to weight-loss interventions, such as GLP-1 receptor agonists and bariatric surgery, attributing hair loss to systemic and metabolic stress rather than permanent hair follicle damage.

This review highlights concerns about dermatological side effects linked to rapid weight loss from glucagon-like peptide-1 receptor agonists used for type 2 diabetes and obesity treatment, such as skin laxity, decreased collagen, and hair loss, emphasizing the importance of managing these while retaining metabolic benefits.

This case report details a 61-year-old man's overdose on oral minoxidil, resulting in systemic side effects like hypotension and edema, which resolved without intervention; similar symptoms were observed in 14 other patients after minoxidil ingestion.

In this retrospective cohort study, researchers found that exposure to 5-alpha reductase inhibitors and spironolactone in female alopecia patients was not linked to an increased risk of developing malignant or benign gynecologic tumors when compared to minoxidil use.

This study explores the role of antidiabetic medications, particularly metformin, GLP-1 receptor agonists, and DPP-4 inhibitors, in managing PCOS, highlighting their combination with hormonal therapies and lifestyle interventions for a comprehensive treatment approach.

In this review, researchers explored key mechanisms underlying androgenetic alopecia, revealing how hormonal, oxidative, inflammatory, and lipid dysregulation suppress hair growth pathways and suggesting new therapeutic targets such as DP2 antagonists and microbiome modulators.